










































Rectal Aberrant Crypt Foci in Humans Are Not
Surrogate Markers for Colorectal Cancer Risk
Isabel Quintanilla, PhD1, María López-Cerón, MD, PhD2, Mireya Jimeno, MD3, Miriam Cuatrecasas, MD, PhD3, Michel Zabalza, MD2,
Leticia Moreira, MD, PhD1, Virginia Alonso, PhD1, Cristina Rodríguez de Miguel, RN2, Jennifer Muñoz, BSc1, Sergi Castellvi-Bel, PhD1,
Josep Llach, MD, PhD2, Antoni Castells, MD, PhD1,2, Francesc Balaguer, MD, PhD1,2, Jordi Camps, PhD1 and Maria Pellisé, MD, PhD1,2
INTRODUCTION: Over the past 20 years, aberrant crypt foci (ACF) have emerged as potential precursors and biomarkers
for colorectal cancer (CRC). However, data regarding their molecular pathogenesis, as well as their
endoscopic and histological identification, remain inconsistent.
METHODS: A wide cohort of ACF from 100 control subjects and 100 case patients, including patients with
adenoma and CRC, were characterized for endoscopic, morphologic, and molecular features.
RESULTS: We observed that among all the endoscopic features evaluated, only the number of large ACF correlated
with CRC risk (P = 0.003), whereas the histological classification, as assessed by 2 different
pathologists, was inconsistent and did not differ between control and case patients. Moreover, only
a few APC and BRAF mutations and no microsatellite instability were detected in our samples. KRAS
mutations were detected in 16.3% of ACF samples, which also exhibited increased MGMT
hypermethylation. However, none of those events were found to be predictive of CRC risk.
DISCUSSION: AlthoughACFmight be preneoplastic lesions of the colon, they are not suitable biomarkers for assessing
CRC progression.
Clinical and Translational Gastroenterology 2019;10:e-00047. https://doi.org/10.14309/ctg.0000000000000047
INTRODUCTION
Aberrant crypt foci (ACF) are the earliest visible lesions in the
colorectum and are considered potential precursors of colorectal
cancer (CRC). They are defined as crypts with altered luminal
openings, thickened epithelium, and larger in size than normal
crypts. In addition, although ACF can arise in both the proximal
and distal colon, they are mostly observed in the distal colon and
rectum (1). ACFwere first detected in the colon of rodents treated
with colon-specific carcinogens (2–4), being later identified in
human patients at a high risk of CRC (5).
The association of the size and number of ACF with CRC risk
in humans is somehow controversial, with studies for and against
these findings (6–12). These lesions also exhibit dysplasia, an
increased proliferative index and some genetic alterations such as
KRAS, APC, and BRAF mutations, commonly observed in ade-
nomas and carcinomas (13). Nevertheless, the frequency and
distribution of these alterations vary substantially between studies
and among CRC risk groups (6,14,15), complicating the clinical
utility of ACF as CRC biomarkers.
The most widely accepted histological approach is to clas-
sify ACF as hyperplastic and dysplastic, as recommended by
the World Health Organization (16). The frequency of dys-
plastic ACF is low (10,11,17,18); however, it seems to have
potential for malignant degeneration (6,19–22). In addition,
studies of hyperplastic ACF have suggested that these, too,
might have malignant potential, albeit via the serrated path-
way of carcinogenesis (23).
High-magnification chromoendoscopy (CE) permits the di-
rect observation ofACF and allows for the identification of several
features that have been correlated with ACF histology and CRC
risk (6,19,23). In fact, the most common definition of ACF is
based on endoscopy crypt patterns after staining with methylene
blue. ACF are clusters of crypts that are stained darker than the
surrounding mucosa, have larger diameters, often with oval or
slit-like lumens and thicker epithelial linings (6). Several human
studies have demonstrated that ACF can be identified and char-
acterized by conventional and electronic CE using magnification
and high-definition scopes (6,7,11,19,20,24). Nevertheless, the
data reported to date remain inconsistent (25), and the rate of
agreement between the presence of ACF and their histologic
confirmation varies substantially (6,7), thus further hindering
their utility as surrogate markers for CRC. Indeed, most ACF
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reportedly remain in a dormant state or even regress and disap-
pear (26,27), and according to 1 multicenter study, rectal ACF
were difficult to reidentify during follow-up examination (11).
Despite evidence supporting the notion that ACF are pre-
cancerous lesions, there are many inconsistences in the data re-
garding their molecular pathogenesis, as well as its endoscopic
and histological identification. Therefore, the aim of this study
was to determine whether rectal ACF are biomarkers of CRC risk
by characterizing the endoscopic, morphologic, and molecular
features of ACF samples collected from subjects without colonic
lesions (controls), with adenoma and CRC.
METHODS
Subjects
This study was approved by the Ethics Committee at the Hospital
Clinic of Barcelona, and all participants provided their written
consent. Individuals were prospectively recruited from the reg-
ular patient agenda of the Endoscopy Unit at the Hospital Clinic
of Barcelona. During the inclusion period, colonoscopy reports in
the Endoscopy Unit were reviewed daily. Individuals with
a colonoscopy not reaching cecum (or ileocolonic anastomosis, if
applicable) and/or with a poor bowel preparation in any colonic
segment were excluded. Subjects were invited to participate in the
study via phone call a few days after the colonoscopy. They were
selected and divided into 2 groups based on their endoscopic
findings: (i) Control group: individuals with a normal colono-
scopy and without a personal history of adenomas or CRC (n5
100) and (ii) Case group: patients with a personal history of CRC
or current CRC (n 5 50) or patients with $1 current colonic
adenomas (n 5 50). Patient exclusion criteria are detailed in
Figure 1. For ACF detection, a different examiner, who was
blinded to each patient’s study group, performed a rectoscopy.
The interval between the colonoscopy and the rectoscopywas less
than 1 month.
Endoscopy assessment
A systematic examination of the distal 10 cm of the rectum was
performed with a high-definition colonoscope (Olympus H180,
Evis Exera II processor, Olympus Europe) in all patients. ACF
were defined as crypts with a larger diameter than the normal
mucosa, a thicker epithelial lining, and a dilated crypt lumen.
ACF that raised.2 mm were considered polyps. The number of
ACF per patient was categorized as less than 5, 5 to 15, or more
than 15. The rectum was examined clockwise, proximal to distal,
to record ACF features and their location, first with narrow-band
imaging (NBI) and then with methylene blue 0.5% CE. CE was
considered the gold standard for ACF detection. The size of ACF,
as assessed by CE, was classified as small (,20 crypts per ACF),
medium (20–40 crypts per ACF), or large (.40 crypts per ACF).
The shape of the crypt lumens, as visualized by CE, was charac-
terized as semicircular-oval, asteroid-like, or irregular. ACF
vascular pattern intensity (VPI) was described as weak, normal,
or strong in comparison with the appearance of the surrounding
mucosa, as visualized by NBI.
Figure 1. Patients’ flowchart.







Normal mucosa and the 5 largest ACF were biopsied for each
patient. ACF were immediately immersed in tissue freezing me-
dium (OCT) and stored at 280 °C, whereas the normal mucosa
was conserved in PBS at280 °C. The tissue sections were stained
with hematoxylin and eosin and analyzed by lightmicroscopy. All
samples were evaluated twice over a period of 6 months by 2
different pathologists (A and B) who were blinded to the endo-
scopic classification and to each other’s diagnoses. Discordant
diagnoses were reviewed to reach a consensus diagnosis. Histo-
logical findings were classified as inadequate sample, normal
mucosa, hyperplastic ACF, and dysplastic ACF, according to the
WHO classification (16). The “serrated morphology” category
was incorporated into our final diagnosis to evaluate the possible
role of ACF in the serrated pathway.
Molecular analysis
For feasibility reasons, molecular characterization was only per-
formed for the first 3 histologically confirmed ACF samples from
each patient. DNA from ACF and normal mucosa was extracted
using the All Prep DNA/RNA Mini Kit (Qiagen, Hilden, Ger-
many) in accordance with the manufacturer’s recommendations
and quantified using a NanoDrop Spectrophotometer ND-1000
(Thermo Fisher Scientific, Waltham, MA).
KRAS mutational analysis. A fragment of the KRAS gene
spanning codons 12 and 13 was amplified by COLD-PCR
using the following primers: F, 5’-GCCTGCTGAAAAT-
GACTGAA-3’, and R, 5’-AGAATGGTCCTGCACCAG
TAA-3’.
APCmutational analysis. APCmutations were analyzed from 2
amplified fragments (A and B) that spanned themajority (82.6%)
of theAPC genemutations. Primer sequences were (i) A-F (5’-CA
GTGAGAATACGTCCACACCT-3’) and B-F (5’-TTTGAGA
GTCGTTCGATTGC-3’) and (ii) A-R (5’-CATTCCACTGCA
TGGTTCAC-3’) and B-R (5’-TGATGACTTTGTTGGCA
TGG-3’).
BRAF mutational analysis. BRAF V600E mutation genotyping
was performed by Real-Time Taqman PCR using primers and
probes designed by Applied Biosystems Custom Genotyping
Assay Service.
Microsatellite instability analysis. The microsatellite instability
(MSI) Analysis System, consisting of 5 nearly monomorphic
mononucleotide markers (BAT-25, BAT-26, NR-21, NR-24, and
MONO-27) and 2 polymorphic pentanucleotide markers (Penta C
andPentaD)were used according to themanufacturer’s guidelines
(Promega, Wisconsin).
Methylation analysis.MGMT gene promoter methylation levels
were investigated using pyrosequencing-based methylation
analysis, as described previously (28).
Statistical analysis
CE and the consensus histological diagnoses were considered the
gold standard for ACF detection and diagnostic confirmation,
respectively. SPSS statistical software (IBM 2012, IBM SPSS
Statistics, Version 20.0. Armonk, NY) was used for data analysis.
Results for continuous variables were summarized using mean
and SD or median and interquartile range for skewed data. Fre-
quencies (%) were used to summarize categorical variables, and
95% confidence intervals were calculatedwhen relevant. Student t
or Mann-Whitney tests were used to compare the distribution of
continuous variables by their outcome. Pearson x2 or Fisher exact
tests were used to test for any association between categorical
variables and outcome. All analyses were exploratory, and 2-
tailed tests with a significance level of 5% were used throughout.
The association between endoscopic features and study group
were adjusted by age and sex using binary logistic regression.
Paired analyses were performed when comparing molecular
changes in normal mucosa and ACF. Inter- and intra-pathologist
concordance for histological diagnosis were calculated by
Weighed k-statistics and defined as follows: fair, 0.21–0.40;
moderate, 0.41–0.60; good, 0.61–0.80; and very good, 0.81–1.00.
RESULTS
Patient baseline characteristics
Two hundred patients (56% female, age 62.9 6 13.8 years) were
included in this study. The control group was composed of more
females, of younger age, than the study group (66% vs 46%, P5
0.05 and 57.62 6 15.58 years vs 68.15 6 9.26 years, P , 0.001,
respectively). Among the patients with adenoma, 29 (58%) had
$1 advanced adenoma. In the CRC group, 22 patients (44%) had
a previous CRC, and 28 (56%) had a current CRC. Inclusion and
exclusion criteria are shown in Figure 1, and colonoscopy indi-
cations are detailed in Table S1 (see Supplementary Digital
Content 1, http://links.lww.com/CTG/A46).
Endoscopic features of ACF
CE detected the presence of at least 1 ACF in 176/200 (88%)
patients. Forty-three individuals (21.5%) exhibited less than 5
ACF, 94 (47.0%) had between 5 and 15 ACF, and 63 (31.5%) had
more than 15 ACF. A total of 1,103 ACF were characterized by
CE, whereas 768 were characterized by NBI. Size evaluation de-
termined that 305 ACF (27.2%) were small, 366 (33.2%) were
medium, and 432 (39.2%) were large. The shape of the crypt
lumens was semicircular-oval in 80.1% of the ACF, asteroid-like
in 10.1%, and irregular in 9.8%. Finally, ACFVPIwas weak in 525
ACF (68.4%), normal in 220 ACF (28.6%), and strong in only 23
ACF (3%).
As is shown in Tables 1 and 2, only the presence of large ACF
was related to the CRC risk group. In fact, the number of large
ACF increased progressively toward CRC risk (control, 6.06%;
adenoma, 20%; CCR, 28%). Conversely, neither the number of
ACF per subject, the lumen morphology, nor VPI was related to
CRC risk.
ACF histology
Although 686 ACF were detected endoscopically, only 553 were
confirmed by histology (38 inadequate samples, 95 normal mu-
cosa) (see Figure S1, Supplementary Digital Content 1, http://
links.lww.com/CTG/A46). According to the consensus diagnosis,
553 ACF samples were classified as hyperplastic ACF (71.6%),
serrated ACF (10.1%), or dysplastic ACF (18.3%) (Figure 2).
Consequently, the diagnostic yield of endoscopy (histologically
confirmed ACF/ACF detected with CE) was 80.6%. Pathologist A
showed a weighed K for intraobserver concordance of 0.59, and
pathologist B 0.71 (P # 0.001). The best weighed K for in-
terobserver concordance was only 0.25 (P, 0.001). Interestingly,
the histology of ACF was not related to gender, sex, or CRC risk
group (Table 2). Although dysplastic and serrated ACF exhibited
an irregular shape more frequently than hyperplastic ACF, their
size and VPI were not associated with ACF histology (Table 3).
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Molecular analysis of ACF
The first 3 histologically confirmed ACF from each patient were
used for molecular analysis, totaling 294 ACF samples. Of these,
128 were from 67 control subjects (47 female (70%); age 58.3 6
15.2 years) and 166 were from 81 case patients, of which 40 were
from patients with adenoma and 41 were from patients with CRC
(32 female (39%); age 67.7 6 9.9 years). Of this cohort of ACF
samples, 146/294(49.7%) were categorized as large lesions. His-
tological examination revealed that 197 ACF (67.0%) were
hyperplastic, 35 (12.0%) serrated, and 62 (21.0%) dysplastic
lesions (see Figure S1, Supplementary Digital Content 1, http://
links.lww.com/CTG/A46).
APC mutation and MSI analysis in ACF
APC mutations were determined for 285/294 (96.9%) ACF
samples. The APC variant E1317Q was found in 5/285 (1.7%)
samples (Table 4); however, these ACF belonged to patients who
exhibited the same variant in their normal mucosa, indicating
Table 1. Analysis of individuals and ACF features predictive of CRC risk adjusted per patient’s age and sex
Control, N = 100 Case, N = 100 Adjusted P value OR
Female (%) 66 (66.0) 46 (46.0) 0.005 0.32
Age (yr 6 SD) 57.62 6 15.58 68.15 6 9.26 0.0001 1.08
No. of ACF per patient 23/48/29 20/46/34 n.s
Categories: ,5/5–15/.15 (%) (23.0/48.0/29.0) (20.0/46.0/34.0)
Patients with:
• At least 1 large ACF (%) 62 (62.0) 78 (78.0) 0.046 2.03
• More than 1 large ACF (%) 41 (41.0) 66 (66.0) 0.002 2.70
• More than 4 large ACF (%) 6 (6.0) 24 (24.0) 0.003 3.47
• One irregular ACF (%) 26 (26.0) 35 (35.0) n.s
• At least 1 dysplastic ACF (%) 32 (32.0) 40 (40.0) n.s
• More than 1 dysplastic ACF (%) 10 (10.0) 11 (11.0) n.s
• At least 1 serrated ACF (%) 19 (19.0) 26 (26.0) n.s
ACF, aberrant crypt foci.
Table 2. Analysis of ACF features predictive of CRC risk adjusted by age and sex
Control, N = 100 Case, N = 100 Adjusted P value OR
Large size 32.1% 45.0% 0.001 1.61
(Large ACF/ACF evaluated by chromoendoscopy) (159/496) (273/607)
Irregular shape 7.4% 11.9% n.s
(Irregular ACF/ACFevaluated by chromoendoscopy) (35/470) (65/547)
Large or irregular 36.8% 54.1% 0.0001 1.76
(Large or irregular ACF/ACF evaluated by
chromoendoscopy)
(173/470) (296/547)
Intensive vascular pattern 2.2% 3.8% n.s
(Hypervascular ACF/ACF evaluated by NBI) (8/369) (15/399)
ACF histologically confirmed 75.6% 84.8% 0.018 1.69
(ACF histologically confirmed/ACF biopsied) (235/311) (318/375)
Dysplastic ACF 19.6% 17.3% n.s
(Dysplastic ACF/histologically confirmed ACF) (46/235) (55/318)
Serrated ACF 10.2% 10.1% n.s
(Serrated ACF/histologically confirmed ACF) (24/235) (32/318)
Hyperplastic ACF 70.2% 72.6% n.s
(Hyperplastic ACF/histologically confirmed ACF) (165/235) (231/318)
ACF, aberrant crypt foci.






that it was germline and not related to ACF formation.MSI status
was evaluated for 276/294 (94.2%) ACF samples. All samples
analyzed were MSS.
BRAF and KRAS mutations in ACF
BRAF and KRAS mutations were examined in 290/294 (98.6%)
and 289/294 (98.3%) ACF samples, respectively. The BRAF
V600Emutation was detected in only 6/290 (2.1%) ACF samples,
whereas KRAS was mutated in 48/289 (16.3%) ACF samples.
Moreover, as described previously, no ACF sample simulta-
neously exhibited BRAF and KRAS mutations (29).
MGMT methylation status analysis in ACF
As KRAS mutations have been previously associated with the
serrated alternative pathway of carcinogenesis (30), we de-
termined the MGMT methylation status in 33 KRAS-mutated
and 75 KRAS wild-type ACF samples, as well as in their sur-
rounding normal mucosa. Overall, the level of methylation was
significantly higher in ACF samples compared with their corre-
sponding normalmucosa (5.546 3.70 vs 4.236 2.31, P5 0.004).
However, there were no differences in the levels of methylation
among the control and case groups or between those ACF sam-
ples with mutated or wild-type KRAS status (see Figure S2A, B
and C, Supplementary Digital Content 1, http://links.lww.com/
CTG/A46). Next, we analyzed the methylation results as a cate-
gorical variable using the mean levels in the normal mucosa
methylation as the cutoff for ACF hypermethylation (mean 6 2
SD, which corresponded to 8.66%). Interestingly, by using this
cutoff, we observed significantly more hypermethylated samples
in the set ofKRASmutated ACF than in the set of ACF displaying
wild-type KRAS (21% vs 5.71%, P 5 0.02). Nevertheless, we did
not detect any difference in the distribution of the hyper-
methylated ACF among the control and case groups or according
to their histology (Tables 4 and 5).
DISCUSSION
The present case-control study uses a translational approach to
evaluate the role of rectal ACF as a precursor lesion ofCRC and its
clinical application as an intermediate end point in CRC carci-
nogenesis. First, we performed in vivo and in situ detection and
characterized ACF by advanced endoscopy in 100 individuals
without colonic lesions and 100 patients at risk of CRC. Second, 2
Figure2.Histological sectionsof 2 aberrant crypt foci, with hyperplastic change, showingnondysplastic distorted architecture of the surfaceepitheliumwith
widening and hyperplastic contour of the luminal end of the crypts (a) (H&E,3100), and dysplastic change with hyperchromatic, cigar-shaped nuclei,
pseudostratification, dense eosinophilic cytoplasm, mitotic figures, and loss of cytoplasmic mucin (b) (H&E,3200).
Table 3. Analysis of ACF features related to histology
Hyperplastic Serrated Dysplastic P value
Large size 59.6% 50.5% 58.9% n.s
(Large ACF/histologically confirmed ACF) (236/396) (33/56) (51/101)
Irregular shape 10.1% 20.4% 20.6% 0.006
(Irregular ACF/histologically confirmed ACF) (39/385) (11/54) (20/97)
Asteroid-like or irregular shape 20.8% 25.9% 35% 0.012
(Asteroid-like or irregular ACF/histologically confirmed ACF) (80/385) (14/54) (34/97)
Intensive vascular pattern 3.9% 5.1% 5.6% n.s
(Hypervascular ACF/histologically confirmed ACF) (12/306) (2/39) (4/71)
Control group 41.7% 42.9% 45.5% n.s
(ACF from the control group/histologically confirmed ACF) (165/396) (24/56) (46/101)
Case group 58.3% 57.1% 54.5% n.s
(ACF from the study group/histologically confirmed ACF) (231/396) (32/56) (55/101)
ACF, aberrant crypt foci.
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different pathologists evaluated a set of 686 ACF samples twice to
reach a consensus diagnosis on the basis of standardized criteria.
Last, amolecular profile of commonCRCalterationswas assessed
for these lesions. Our results showed that rectal ACF may be
preneoplastic lesions and play a role in CRC carcinogenesis;
however, they are not reliable biomarkers because their mor-
phological and molecular findings were not consistent and there
was no association with the risk group.
Previous studies have reported the diagnostic yield of endos-
copy when using histology as gold standard to be between 60%
and 68% (11,31). In our cohort, 80% of the lesions identified by
endoscopy as potential ACFwere corroborated by their histology,
thus indicating that high-definition CE was a suitable technique
for detecting these subtle lesions (32).
Previously, it has been reported that there is a stepwise in-
crease in the number and prevalence of rectal ACF in relation to
the CRC risk group (18,24). However, in accordance with data
from multicenter studies (10,11), we did not find the number of
ACF to be associated with CRC. On the other hand, although
none of the other endoscopic features were predictive of CRC
risk, we found that the number of large ACF was associated with
the CRC risk group. Unfortunately, this endoscopic feature
was not associated with a specific histopathological diagnosis
or molecular pathway, rendering this observation of dubious
clinical utility.
Previous data showed that dysplastic ACF were specially re-
lated to CRC risk (19). In addition, elongated and asteroid-like
lumens are characteristic of dysplasia and hyperplasia, re-
spectively (20,33). However, we only found irregular lumens to be
associatedwith dysplastic and serratedACF. This is in accordance
with a previous study that showed that endoscopic features were
inconsistent across endoscopists and did not accurately predict
histology (31).
Histological characterization of ACF remains a challenge.
There is significant variability across numerous studies in terms
of the tissue sampling procedures and ACF classification (34,35).
Two pathologists examined all specimens, twice, in random or-
der, yet neither the interobserver nor the intraobserver con-
cordances were satisfactory. Considering that we are evaluating
very subtle changes, the small size of the samples (average of
2 mm) and the lack of orientation during sampling may have
influenced these poor results. Nonetheless, this limitation reflects
the difficulties in classifying ACF morphologically and suggests
the necessity of a more careful and objective standardization
among pathologists, such as examining different ACF sections to
accurately assess dysplasia in these lesions, which may be focally
represented. Our cohort of ACF samples wasmainly composed of
hyperplastic lesions, accounting for only 18.5%of dysplastic ACF,
which is in agreement with the previously reported low preva-
lence of dysplasia. In fact, some studies did not even detect dys-
plastic ACF (10,17). Furthermore, as the appearance of sessile
serrated polyps has been mainly associated with the proximal
colon (36,37), we were only able to detect a modest percentage of
serrated ACF. Nevertheless, we did not find any histological
category to be predictive of CRC risk.
Several previous studies have stated that ACF harbor genetic
alterations that might lead to malignant transformation, but
these data remain controversial (14,15,38). APCmutations are
considered an early event in CRC carcinogenesis; however,
several studies have reported that APC mutations are found in
ACF lesions from patients with familial adenomatous poly-
posis, whereas they are infrequent in sporadic ACF (15,38,39).
Similarly, in our cohort of ACF samples, we found APC alter-
ations to be rare. In addition, although mutations in BRAF are
commonly associated with serrated lesions from the proximal
colon, including ACF (40–42), others have detected them in
only 2% of sporadic rectal ACF (14). In agreement with these
findings, we observed BRAF mutations in only 2% of our ACF
samples. In addition, although MSI has been detected in ACF
from patients with Lynch syndrome (43), sporadic ACF are
known to exhibit a lower frequency of MSI (42,44,45). Ac-
cordingly, we did not observe MSI in any of the ACF samples
analyzed (35).
Last, several investigations have consistently reported a high
but variable incidence of KRAS mutations in sporadic ACF
(15,38). The discrepancies regarding the frequency of KRAS
mutations among studies could be due to the different types and
sizes of study populations. Accordingly, we detected KRAS
mutations in 16.3% of ACF samples; however, there was no
association with the case group, similar to what has been ob-
served previously (6,15). Moreover, MGMT promoter hyper-
methylation and its association with KRAS mutations have
been described in the early stages of CRC (46,47). We also
observed an association between KRAS mutation and MGMT
Table 4. ACF molecular features related to the CRC risk group
Control Case P value
KRAS mutations 17/124 (13.7%) 30/165 (18.2%) n.s
BRAF mutations 3/128 (2.3%) 3/162 (1.9%) n.s
APC mutations 0/127 (0%) 5/158 (3.2%) n.s
MGMT hypermethylation 6/37 (16.2%) 6/71 (8.5%) n.s
ACF, aberrant crypt foci.
Table 5. ACF molecular features related to histology
Hyperplastic Serrated Dysplastic P value
KRAS mutations 33/195 (16.9%) 2/35 (5.7%) 12/59 (20.3%) n.s
BRAF mutations 3/193 (1.6%) 1/35 (2.9%) 2/62 (3.2%) n.s
APC mutations 2/190 (1.1%) 1/35 (2.9%) 2/60 (3.3%) n.s
MGMT hypermethylation 10/76 (13.2%) 0/9 (0%) 2/23 (8.7%) n.s
ACF, aberrant crypt foci.






promoter hypermethylation in our ACF samples, although
those ACF were not predictive of CRC risk.
Before reaching definitive conclusions, some limitations
should be acknowledged. First, the cross-sectional design of this
study precludes us from raising any associations of causality.
Second, the study cohort was composed of more males, of older
age, both variables associated with CRC risk; however, we in-
troduced them in the multivariate analysis. Another potential
limitation is the presence in the control group of subjects with
gastrointestinal symptoms (see Table S1, Supplementary Digi-
tal Content 1, http://links.lww.com/CTG/A46), which could be
a hallmark of colonic lesions, despite a complete normal recent
colonoscopy. This possibility is remote because those patients
underwent a high-quality colonoscopy just before inclusion. Last,
the frozen and crush artifact, orientation of the sample and the
small size of the biopsies may result on scarce or no representa-
tion of the lesion, even to little alteration of the morphology and
thus to the difficult pathological interpretation or limitation of an
accurate histological diagnosis of some of the early lesions. In
addition, by examining only the rectum, we may have limited the
type of ACF samples obtained and affected our rates of preva-
lence. Nevertheless, in previous studies, the vast majority of these
lesions are detected in the distal colon, and rectal ACF have been
described as representative of the rest of the colon (10). In fact, the
evaluation of proximal ACF remains limited and has resulted in
the detection of few gene mutations other than KRAS or BRAF,
such as EGFR orFLT3 (1,41). In addition, if a firm relationship
between rectal ACF features and CRC risk would have been
proven, we could use rectoscopy as a tool for identifying those
patients at risk of CRC that would clearly benefit from screening
with a complete colonoscopy. In particular, subjectswith no rectal
ACFwould not need anymore tests because theywould be at very
low risk, whereas those with dysplastic rectal ACF would need
a complete colonoscopy to rule out colonic lesions. Last, by
performing microdissection of our samples, we could have been
able to slightly increase the frequency of the genetic alterations we
observed; however, other studies have not used this technique
(11,21,31,42), and the large number of samples limited the fea-
sibility of accomplishing this with our resources. Furthermore, we
considered that the methodology of our molecular analysis was
sensitive enough for our purpose.
In conclusion, this large-scale study of ACF demonstrated
that there is no consistent morphological characteristic that
would enable us to recommend ACF as biomarkers for CRC
risk. Our molecular analysis found that KRAS mutations and
MGMT promoter hypermethylation might be responsible for
ACF formation. Nevertheless, as none of the genomic alter-
ations observed in ACF correlated with the CRC risk group, our
results indicate that ACF might merely be preneoplastic
lesions, but not suitable as an intermediate end point for CRC
carcinogenesis.
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